Open AccessExpression of the immune checkpoint B7-H3 in tumor and its soluble form in serum of patients with bone neoplasms
Author(s) -
N. E. Kushlinskii,
О. В. Ковалева,
А. А. Алферов,
Yu B Kuzmin,
Е. А. Сушенцов,
И. С. Стилиди
Publication year - 2021
Publication title -
alʹmanah kliničeskoj mediciny
Language(s) - English
Resource type - Journals
eISSN - 2587-9294
pISSN - 2072-0505
DOI - 10.18786/2072-0505-2021-49-013
Subject(s) - immune system , transmembrane protein , glycoprotein , antigen , receptor , cancer research , immunology , biology , microbiology and biotechnology , chemistry , medicine , genetics
B7-H3, also called CD276, is a type I transmembrane glycoprotein that is encoded on human chromosome 15. It was discovered back in 2001. The original study described it as a positive co-stimulant, as it can stimulate T-cell response and IFN-y production. However, recent researches have shown that B7-H3 is involved in T-cell inhibition. A B7-H3 receptor has not been yet identified, and this may explain the complex immunomodulatory activity of B7-H3, as it can have more than one binding partner with different functions. Expression of the B7-H3 protein has been found on activated immune cells such as T-cells, NK cells and antigen presenting cells. Interestingly, it is overexpressed in a wide range of tumor cells and is associated with disease progression and outcome. The soluble form of this protein is also of particular interest. Increased sB7-H3 levels in the plasma of bone tumor patients might be their important diagnostic criterion.